top of page

Thymosin Alpha 1 mod 5mg

$110.00Price
Excluding Sales Tax
Thymosin Alpha 1 mod is an Immune‑modulating peptide analog linked to T‑cell maturation and cytokine balance. Potential benefits include support for immune responsiveness and vaccine adjuvancy.
Quantity

  • Thymosin Alpha-1 Mod – Research & Chemical Profile

    Overview

    Thymosin Alpha-1 (often abbreviated Tα1) is a naturally occurring thymic peptide involved in regulating the immune response. “Thymosin Alpha-1 Mod” refers to a modified or synthetic version of this 28-amino-acid peptide designed to enhance stability, absorption, or activity in research settings. It’s not an FDA-approved drug and is sold for laboratory and research purposes only.

     

    Chemical Structure / Identifiers

    - Sequence: H-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (28 aa; modifications vary by supplier)
    - Parent Peptide: Thymosin Alpha-1 (Tα1), originally isolated from thymus tissue
    - Modifications: May include N-terminal acetylation, salt forms, or other stabilizing changes (not standardized across vendors)
    - Registry/DB: Parent Tα1 is cataloged in PubChem as “thymalfasin”

     

    Primary Research Focus

    - Immune Modulation: Preclinical and limited clinical data indicate Tα1 can enhance T-cell function, modulate cytokine production, and support host defense in viral or immunocompromised models.
    - Anti-inflammatory Signaling: Evidence of balancing Th1/Th2 immune responses and reducing overactive inflammatory cascades.
    - Adjuvant Potential: Studied as a vaccine adjuvant and in combination with standard therapies in infectious disease, oncology, and immune disorders.

     

    Research Context & Limitations

    - Non-Standardized Modifications: “Tα1 Mod” isn’t a single chemical entity; purity, sequence confirmation, and biological activity can differ by source.
    - Regulatory Status: Neither the original peptide nor modified analogues are approved by major regulators for prevention or treatment of disease; laboratory use only.
    - Human Data: Some published trials exist for the original thymalfasin, but modified versions lack established dosing, pharmacokinetics, or safety profiles.

     

    Key Literature & References

    - PubChem Compound Summary: Thymosin Alpha-1 (Thymalfasin) – https://pubchem.ncbi.nlm.nih.gov/compound/Thymosin-alpha1
    - “Thymosin Alpha-1 in Immune Regulation” – Review article, Int J Immunopharmacol 2020 – https://pmc.ncbi.nlm.nih.gov/articles/PMC7674483/
    - “Thymosin Alpha-1 as an Immune Enhancer in Infectious Disease and Cancer” – Front Immunol 2021 – https://pmc.ncbi.nlm.nih.gov/articles/PMC8245973/

     

    Disclaimer

    For research background only. This information is not medical advice. “Thymosin Alpha-1 Mod” refers to modified research versions of the parent peptide and has not been validated in controlled human trials.

bottom of page